|
WO2019224385A2
|
|
Combined bispecific antibody and immuno-oncology therapies
|
|
WO2019219978A1
|
|
Anti-ox40 antagonistic antibodies for the treatment of autoimmune diseases
|
|
US2019135918A1
|
|
Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
|
SG11201910172VA
|
|
Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
|
|
WO2018185675A1
|
|
Substituted oxoazetidine analogues as ror gamma modulators
|
|
WO2018116285A1
|
|
Substituted morpholine derivatives as ror gamma modulators
|
|
KR20190095941A
|
|
New TNFR Agonists and Their Uses
|
|
WO2018042342A1
|
|
1,2,3-benzotriazole derivatives as ror gamma t modulators
|
|
EP3446710A1
|
|
Methods of inactivating viral contaminants
|
|
WO2017191532A1
|
|
Pharmaceutical foam composition
|
|
WO2017134292A1
|
|
Anti-ox40 antagonistic antibodies for the treatment of atopic dermatitis
|
|
WO2017199103A1
|
|
Benzamide compounds as ror gamma modulators
|
|
WO2017051319A1
|
|
Aryl and heteroaryl ether compounds as ror gamma modulators
|
|
KR20180044384A
|
|
As a ROR gamma modulator, novel carbocyclic compounds
|
|
BR112018001469A2
|
|
compound, pharmaceutical composition and use of a compound
|
|
CN107820489A
|
|
PGES 1 suppresses the polymorph of triazolone compound
|
|
US2017274147A1
|
|
Drug delivery device
|
|
WO2016193894A1
|
|
Treatment of respiratory disorders using ror- gamma inhibitors
|
|
WO2016128905A1
|
|
Thienopyrrole compounds as s-nitrosoglutathione reductase inhibitors
|
|
US2017362327A1
|
|
Anti-trka antibodies with enhanced inhibitory properties and derivatives thereof for use in treating bone associated pain
|
